Blueprint Medicines (BPMC) News Today $96.48 +1.09 (+1.14%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Blueprint Medicines Co. (NASDAQ:BPMC) Insider Ariel Hurley Sells 1,819 SharesDecember 17 at 4:35 AM | insidertrades.comBlueprint Medicines Co. (NASDAQ:BPMC) Position Boosted by Geode Capital Management LLCGeode Capital Management LLC boosted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 1.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,480,187 shares of the biotechnology companyDecember 17 at 4:15 AM | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $169,639.94 in StockBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Ariel Hurley sold 1,819 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the sale, the insider now owns 14,967 shares of the company's stock, valued at approximately $1,395,822.42. This trade represents a 10.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.December 16 at 10:20 PM | marketbeat.comBarclays PLC Reduces Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Barclays PLC lessened its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 27.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 171,196 shares of the biotechnology company's stock after sellinDecember 16 at 4:22 AM | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short InterestBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 4,190,000 shares, an increase of 7.2% from the November 15th total of 3,910,000 shares. Based on an average daily trading volume, of 628,200 shares, the short-interest ratio is currently 6.7 days.December 15 at 11:34 PM | marketbeat.comAnalysts Set Blueprint Medicines Co. (NASDAQ:BPMC) Price Target at $122.11December 14, 2024 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Given Buy Rating at GuggenheimDecember 13, 2024 | americanbankingnews.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by State Street CorpState Street Corp lifted its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 16.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,765,702 shares of the bioDecember 12, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twenty-one ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have assigneDecember 11, 2024 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Blueprint Medicines (NASDAQ:BPMC)December 11, 2024 | americanbankingnews.comBlueprint Medicines: A Promising Investment with Innovative Treatments and Strong Financial PositionDecember 10, 2024 | markets.businessinsider.comZimmer Partners LP Invests $1.95 Million in Blueprint Medicines Co. (NASDAQ:BPMC)Zimmer Partners LP acquired a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 21,100 shares of the bioteDecember 8, 2024 | marketbeat.comCastleark Management LLC Has $3.14 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)Castleark Management LLC trimmed its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 13.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,990 shares of the biotechnology company's stock afterDecember 8, 2024 | marketbeat.comWellington Management Group LLP Boosts Stake in Blueprint Medicines Co. (NASDAQ:BPMC)Wellington Management Group LLP boosted its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 22.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,964,610 shares of the biotechDecember 8, 2024 | marketbeat.comBlueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual MeetingDecember 7, 2024 | prnewswire.comHolocene Advisors LP Has $1.57 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)Holocene Advisors LP cut its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 98.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,914 shares of the biotechnology company's stock after selling 926,550 shares during thDecember 7, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stake in Blueprint Medicines Co. (NASDAQ:BPMC)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 24.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 227,911 shares of the biotechnology company's stock after sDecember 6, 2024 | marketbeat.comReadystate Asset Management LP Purchases New Shares in Blueprint Medicines Co. (NASDAQ:BPMC)Readystate Asset Management LP acquired a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 56,500 shares of the biotechnology company's stock, valued at approximately $5,226,000. Readystate ADecember 5, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $45.89 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)Jacobs Levy Equity Management Inc. raised its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 161.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 496,087 shares of the biotechnology company's stDecember 4, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) CEO Sells $227,299.80 in StockDecember 4, 2024 | insidertrades.com25,100 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Erste Asset Management GmbHErste Asset Management GmbH bought a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 25,100 shares of the biotechnology company's stock, valued at approximately $2,323December 3, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Sees Significant Decrease in Short InterestBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) was the target of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 3,910,000 shares, a drop of 5.3% from the October 31st total of 4,130,000 shares. Based on an average trading volume of 639,000 shares, the days-to-cover ratio is currently 6.1 days.December 3, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi Sells 2,274 SharesDecember 3, 2024 | insidertrades.comThe Manufacturers Life Insurance Company Reduces Position in Blueprint Medicines Co. (NASDAQ:BPMC)The Manufacturers Life Insurance Company reduced its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 11.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 149,996 shares of the biotDecember 2, 2024 | marketbeat.comEdgestream Partners L.P. Has $5.19 Million Stake in Blueprint Medicines Co. (NASDAQ:BPMC)Edgestream Partners L.P. increased its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 443.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 56,123 shares of the biotechnology company's stock after purchasing an additional 45,800 sharesDecember 1, 2024 | marketbeat.comFred Alger Management LLC Trims Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Fred Alger Management LLC trimmed its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 31.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,110 shares of the biotechnology company's stoDecember 1, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 50,736 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Charles Schwab Investment Management Inc. grew its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 9.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 597,232 shares of the biotechnology coDecember 1, 2024 | marketbeat.comFmr LLC Sells 316,913 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Fmr LLC trimmed its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 6.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,516,771 shares of the biotechnology company's stockNovember 30, 2024 | marketbeat.comEventide Asset Management LLC Acquires 117,019 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Eventide Asset Management LLC lifted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 50.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 348,704 shares of the biotechnology company's stock after purchNovember 29, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Alkeon Capital Management LLCAlkeon Capital Management LLC lessened its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 19.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 718,928 shares of the biotechnology compNovember 29, 2024 | marketbeat.comCitigroup Inc. Grows Position in Blueprint Medicines Co. (NASDAQ:BPMC)Citigroup Inc. raised its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 19.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 143,441 shares of the biotechnology company's stock after acquiring anNovember 29, 2024 | marketbeat.comAlly Bridge Group NY LLC Has $9.81 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)Ally Bridge Group NY LLC raised its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 40.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 106,080 shares of the biotechnology company's stock after buying an additional 3November 28, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Acquires 82,693 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Massachusetts Financial Services Co. MA increased its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 48.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 252,236 shaNovember 26, 2024 | marketbeat.comIntech Investment Management LLC Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC)Intech Investment Management LLC acquired a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,511 shaNovember 26, 2024 | marketbeat.comPitcairn Co. Has $954,000 Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Pitcairn Co. boosted its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 127.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 10,315 shares of the biotechnology company's stock after acquiring an additional 5,783 shares during thNovember 25, 2024 | marketbeat.comBNP PARIBAS ASSET MANAGEMENT Holding S.A. Invests $6.47 Million in Blueprint Medicines Co. (NASDAQ:BPMC)BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 69,887 shares ofNovember 25, 2024 | marketbeat.comAlgert Global LLC Increases Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Algert Global LLC increased its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 40.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 92,236 shares of the biotechnology compNovember 24, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Holdings Trimmed by Eagle Asset Management Inc.Eagle Asset Management Inc. lowered its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 18.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 154,652 shares of the biotechnology coNovember 24, 2024 | marketbeat.comPrincipal Financial Group Inc. Decreases Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Principal Financial Group Inc. reduced its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 81.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,038 shares of the biotechnology companyNovember 24, 2024 | marketbeat.comFY2024 Earnings Forecast for BPMC Issued By Zacks ResearchBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Equities research analysts at Zacks Research issued their FY2024 earnings per share estimates for Blueprint Medicines in a research note issued to investors on Monday, November 18th. Zacks Research analyst A. Chakraborty forecasts that the bioNovember 21, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Segall Bryant & Hamill LLCSegall Bryant & Hamill LLC grew its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 11.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 141,622 shares of the biotechnology company'November 21, 2024 | marketbeat.comVictory Capital Management Inc. Trims Position in Blueprint Medicines Co. (NASDAQ:BPMC)Victory Capital Management Inc. lessened its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 28.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 190,361 shares of the biotechnology cNovember 20, 2024 | marketbeat.comFirst Turn Management LLC Has $16.55 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)First Turn Management LLC reduced its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 3.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 178,929 shares of the biotecNovember 19, 2024 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Receives "Market Outperform" Rating from JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Monday.November 18, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Prime Capital Investment Advisors LLCPrime Capital Investment Advisors LLC trimmed its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 65.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,464 shares of the biotechnology company'sNovember 17, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Short Interest UpdateBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 4,130,000 shares, an increase of 14.1% from the October 15th total of 3,620,000 shares. Based on an average trading volume of 607,600 shares, the short-interest ratio is currently 6.8 days.November 16, 2024 | marketbeat.comBlueprint Medicines’ Promising Pipeline Developments Support Buy RatingNovember 16, 2024 | markets.businessinsider.comBlueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Rating of "Moderate Buy" from AnalystsBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) has received an average rating of "Moderate Buy" from the twenty-one analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recNovember 16, 2024 | marketbeat.comBlueprint Medicines: Hold Rating Amidst Future Research Potential and Clinical UncertaintiesNovember 16, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)November 16, 2024 | markets.businessinsider.com Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Secret Manhattan Project (Ad)On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking. Click here and I’ll show you exactly how to position your money BPMC Media Mentions By Week BPMC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPMC News Sentiment▼0.880.72▲Average Medical News Sentiment BPMC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPMC Articles This Week▼136▲BPMC Articles Average Week Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TEVA News Today BGNE News Today MRNA News Today VTRS News Today SMMT News Today GMAB News Today RDY News Today SRPT News Today CTLT News Today PCVX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BPMC) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
